Form 4: Septerna Inc. Insider Sells Shares Under 10b5-1 Plan

Septerna Inc. SVP Daniel D. Long sold company stock valued at over $100,000 through a pre-arranged 10b5-1 plan, while also acquiring shares via stock options.

Summary

• Daniel D. Long, SVP of Drug Discovery at Septerna, Inc., reported transactions involving company common stock.
• On July 1, 2026, Long acquired 3,333 shares of common stock at a price of $2.76 per share, acquired through a stock option.
• Also on July 1, 2026, Long sold 2,100 shares at a weighted average price of $34.0964 and 1,233 shares at a weighted average price of $34.8141.
• These sales were executed under a Rule 10b5-1(c) trading plan adopted on March 20, 2026.
• Following these transactions, Long beneficially owns 96,412 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the sale of shares by a senior executive, despite the use of a 10b5-1 plan. The acquisition of shares at a lower price and subsequent sale at a higher price is a standard option exercise and sale, but the net reduction in beneficial ownership by an insider warrants caution.

Positives

• Acquisition of 3,333 shares of common stock at a favorable price of $2.76 per share through stock options.
• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating adherence to compliance and risk management strategies.

Negatives

• Sale of a total of 3,333 shares of common stock by a senior officer, potentially signaling a lack of confidence or need for personal liquidity.
• The sales occurred at prices significantly higher than the acquisition price of the stock options, realizing gains for the reporting person.

Risks

• The sale of shares by a key executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the timing of sales relative to company performance or news could still raise scrutiny.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on completed transactions.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives needing to diversify or manage personal finances. However, the market often scrutinizes such sales, especially if they occur during periods of company volatility or before significant news.

Stakeholder Impact

• Shareholders: May view the sale by a senior executive with some concern, potentially impacting short-term stock sentiment.
• Employees: The sale might be observed, but the use of a 10b5-1 plan mitigates concerns about insider trading.
• Management: Demonstrates adherence to compliance protocols for personal trading.

Next Steps

• The reporting person may continue to execute trades under the existing Rule 10b5-1 plan.
• The company may provide further information upon request from the SEC or security holders regarding the specific sale prices.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established 10b5-1 plan. While the sale of shares by an executive can be a negative signal, the structured nature of the sale suggests it's for personal financial planning rather than a reflection of negative company outlook. The acquisition of shares via options at a lower price and subsequent sale at a higher price is a standard exercise. Without further negative financial or operational news, a 'hold' recommendation is appropriate, pending broader company performance.

Keywords

Form 4, Insider Trading, Septerna Inc., SEPN, Stock Options, Rule 10b5-1, Beneficial Ownership, Executive Sales, Drug Discovery